PMID- 37217140
OWN - NLM
STAT- MEDLINE
DCOM- 20230625
LR  - 20231118
IS  - 1873-2968 (Electronic)
IS  - 0006-2952 (Linking)
VI  - 213
DP  - 2023 Jul
TI  - The mTOR signalling in corneal diseases: A recent update.
PG  - 115620
LID - S0006-2952(23)00211-3 [pii]
LID - 10.1016/j.bcp.2023.115620 [doi]
AB  - Corneal diseases affect 4.2 million people worldwide and are a leading cause of 
      vision impairment and blindness. Current treatments for corneal diseases, such as 
      antibiotics, steroids, and surgical interventions, have numerous disadvantages 
      and challenges. Thus, there is an urgent need for more effective therapies. 
      Although the pathogenesis of corneal diseases is not fully understood, it is 
      known that injury caused by various stresses and postinjury healing, such as 
      epithelial renewal, inflammation, stromal fibrosis, and neovascularization, are 
      highly involved. Mammalian target of rapamycin (mTOR) is a key regulator of cell 
      growth, metabolism, and the immune response. Recent studies have revealed that 
      activation of mTOR signalling extensively contributes to the pathogenesis of 
      various corneal diseases, and inhibition of mTOR with rapamycin achieves 
      promising outcomes, supporting the potential of mTOR as a therapeutic target. In 
      this review, we detail the function of mTOR in corneal diseases and how these 
      characteristics contribute to disease treatment using mTOR-targeted drugs.
CI  - Copyright (c) 2023 Elsevier Inc. All rights reserved.
FAU - Li, Xiang
AU  - Li X
AD  - Department of Ophthalmology, the First Affiliated Hospital of Zhejiang 
      University, Hangzhou, Zhejiang Province, China.
FAU - Chen, Kuangqi
AU  - Chen K
AD  - Department of Ophthalmology, the First Affiliated Hospital of Zhejiang 
      University, Hangzhou, Zhejiang Province, China.
FAU - Wang, Zixi
AU  - Wang Z
AD  - Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang 
      University School of Medicine, Hangzhou, China.
FAU - Li, Jiayuan
AU  - Li J
AD  - Department of Ophthalmology, the First Affiliated Hospital of Zhejiang 
      University, Hangzhou, Zhejiang Province, China.
FAU - Wang, Xiawei
AU  - Wang X
AD  - Department of Ophthalmology, the First Affiliated Hospital of Zhejiang 
      University, Hangzhou, Zhejiang Province, China.
FAU - Xie, Chen
AU  - Xie C
AD  - Department of Ophthalmology, the First Affiliated Hospital of Zhejiang 
      University, Hangzhou, Zhejiang Province, China. Electronic address: 
      xiechenzju@163.com.
FAU - Tong, Jianping
AU  - Tong J
AD  - Department of Ophthalmology, the First Affiliated Hospital of Zhejiang 
      University, Hangzhou, Zhejiang Province, China. Electronic address: 
      idrtong@zju.edu.cn.
FAU - Shen, Ye
AU  - Shen Y
AD  - Department of Ophthalmology, the First Affiliated Hospital of Zhejiang 
      University, Hangzhou, Zhejiang Province, China. Electronic address: 
      idrshen@zju.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20230520
PL  - England
TA  - Biochem Pharmacol
JT  - Biochemical pharmacology
JID - 0101032
RN  - W36ZG6FT64 (Sirolimus)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - EC 2.7.1.1 (MTOR protein, human)
SB  - IM
MH  - Humans
MH  - *Corneal Diseases/drug therapy
MH  - Inflammation/pathology
MH  - Signal Transduction
MH  - Sirolimus/pharmacology/therapeutic use
MH  - *TOR Serine-Threonine Kinases/metabolism
OTO - NOTNLM
OT  - Autophagy
OT  - Cornea
OT  - Immunosuppression
OT  - Inflammation
OT  - Rapamycin
OT  - mTOR
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/05/23 01:06
MHDA- 2023/06/19 13:08
CRDT- 2023/05/22 19:22
PHST- 2023/03/23 00:00 [received]
PHST- 2023/05/16 00:00 [revised]
PHST- 2023/05/16 00:00 [accepted]
PHST- 2023/06/19 13:08 [medline]
PHST- 2023/05/23 01:06 [pubmed]
PHST- 2023/05/22 19:22 [entrez]
AID - S0006-2952(23)00211-3 [pii]
AID - 10.1016/j.bcp.2023.115620 [doi]
PST - ppublish
SO  - Biochem Pharmacol. 2023 Jul;213:115620. doi: 10.1016/j.bcp.2023.115620. Epub 2023 
      May 20.